Clinical calculator summary
Original 2001 Tomita spinal-metastasis score
Clinical calculator summary
Original 2001 Tomita spinal-metastasis score
A three-factor additive score using primary-tumor growth, visceral metastases, and bone-metastasis distribution.
Evidence-based context for fast calculator use
- Purpose:
- Reproduce the original score and its four proposed strategy bands without turning them into current individualized recommendations.
- Population:
- Baseline assessment of patients with established spinal metastases.
- Factors:
- Primary-tumor growth category, Clinician-assessed visceral-metastasis treatability, Solitary or isolated versus multiple bone metastases
- Reference:
- Tomita et al. Spine. 2001;26(3):298-306. doi:10.1097/00007632-200102010-00016.
Pin your most used calculators here by clicking the star in the dropdown.
Tomita Score (Spine Mets)
Clinical Context & Background
This calculator reproduces the original 2001 Tomita spinal-metastasis score. It adds semantic categories for primary-tumor growth, clinician-assessed visceral-metastasis treatability, and solitary/isolated versus multiple bone metastases.
The four source bands remain separate: 2-3 for long-term local control, 4-5 for middle-term local control, 6-7 for short-term palliation, and 8-10 for nonoperative supportive care. The associated strategies are historical proposals from the original study, not current individualized treatment recommendations.
Use only for baseline assessment of established spinal metastases. It is not for screening, diagnosis, post-treatment reassessment, or autonomous treatment selection. Contemporary multidisciplinary assessment remains necessary.
Formula Logic
Original 2001 Tomita score = primary-tumor growth points (slow 1, moderate 2, rapid 4) + visceral-metastasis points (none 0, treatable 2, untreatable 4) + bone-metastasis points (solitary or isolated 1, multiple 2). Total range 2-10.Reference Data
| Total Score | Treatment Goal | Prognostic Group |
|---|---|---|
| 2 - 3 | Wide or marginal excision | Long-term local control |
| 4 - 5 | Marginal or intralesional excision | Middle-term local control |
| 6 - 7 | Palliative surgery | Short-term palliation |
| 8 - 10 | Nonoperative supportive care | Supportive care |
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
Clinical Workflow
Use, Interpret, And Continue The Patient Pathway
Expand for workflow guidance, limitations, examples, and related next steps.
When To Use
- Use at baseline after spinal metastases are established.
- Use clinician assessment to classify visceral metastases as none, treatable, or untreatable.
How To Interpret
- Add the three source-defined contributions for a total from 2 to 10.
- Keep scores 6-7 and 8-10 separate because the original study proposed different strategy bands.
What To Do Next
- Discuss the result in contemporary multidisciplinary context.
- Base treatment decisions on current disease, neurologic, mechanical, systemic, and patient-specific assessment rather than this score alone.
Limitations
- Historical strategies are not current individualized treatment recommendations.
- Not for screening, diagnosis, post-treatment reassessment, or autonomous treatment selection.
- Visceral-metastasis treatability is a clinical judgment rather than a calculator-derived finding.
Validated Population
Patients with established spinal metastases evaluated in the original 2001 surgical-strategy study.
Calculation verification history
Verified
Calculation verification history
Verified: Production browser revalidation
- Five source-backed Tomita cases passed through visible production controls across scores 2, 3, 4, 7, and 10.
- No unexpected N/A, literal undefined value, stale control, or browser-console error was observed.
Case-level evidence is retained in validation/browser-revalidation/tomita-spine-metastases-surgical-score-2026-08-03.json.
: Production browser validation
- Ten source-backed cases were exercised on the public production route through visible browser controls; 10/10 case records passed their expected-versus-observed assertions across 11 visible submissions.
- Overall browser status: failed-console. medium: Production emitted minified React error #418 during route loads/reloads used by this run.
- Case-level inputs, expected and observed results, reset/repeat behavior, failure reproductions, and console evidence are retained in the production-browser evidence record.
Case-level production evidence is retained in validation/browser-production/tomita-spine-metastases-surgical-score.json.
: Full validation test
- 320/320 exhaustive source-combination, score-boundary, strict-input, UI/reset, trace, wording, immutability, registry, and no-panel checks passed with zero score or classification mismatches.
- Scope is the original 2001 baseline Tomita score for established spinal metastases; no panel calculates Tomita or inherits this status.
: Calculation and input-contract correction
- Replaced favorable point-coded defaults and unsafe Object.values/Number summation with three required semantic categories and exact-key validation.
- Restored separate score 6-7 short-term-palliation and score 8-10 nonoperative-supportive-care source rows, preventing supportive-care cases from being presented as palliative surgery.
- Changed bone wording from spine only to solitary or isolated, and added immutable contributions, reconciled trace, matched source row, clinician-assessed visceral treatability, and non-prescriptive historical scope.
Verification confirms the calculator implementation against the cited model; it is not independent clinical validation, regulatory approval, or medical advice.
Related Tools
Frequently Asked Questions
When should Tomita Score (Spine Mets) be used?
Use it for patients undergoing skeletal metastasis stability, fracture-risk, survival, or operative assessment when all required inputs and the intended clinical setting are confirmed.
Can Tomita Score (Spine Mets) determine treatment by itself?
No. Interpret the result with the cited evidence, complete clinical assessment, current guidelines, and patient-specific goals.
Evidence-based oncology decision support. Verify with clinical guidelines.